FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | HPV | Clinical Trial Results

HPV vax successfully treats precancerous lesions

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools
  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

Millions of women who carry the human papillomavirus suffer from precancerous lesions. But a small study indicates that an HPV vaccine may either improve their condition or cure it altogether, preventing malignancies in the vulva.

In a small trial, researchers tested the vaccine on 20 women who suffered from these lesions. And four out of five patients reported that the lesions had either been reduced or eliminated. Half had no sign of the lesions two years after treatment.

"This shows that it is possible to vaccinate against chronic disease, as well as treat HPV-induced premalignance," said study co-author Sjoerd H. van der Burg. If this new approach is proven in larger trials, women will have a shot at replacing surgery or laser and freezing treatments with the vaccine.

- read the story from U.S. News & World Report 

Related Articles:
FDA experts support apps for Cervarix, Gardasil
Acclaimed scientist preps first skin cancer vax trial


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Vaccine   HPV   Clinical Trial Results